{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:53:06Z","timestamp":1795085586983,"version":"4.10.2"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nonalcoholic steatohepatitis (NASH) is a major cause of liver fibrosis with increasing prevalence worldwide. Currently there are no approved drugs available. The development of new therapies is difficult as diagnosis and staging requires biopsies. Consequently, predictive plasma biomarkers would be useful for drug development. Here we present a multi-omics approach to characterize the molecular pathophysiology and to identify new plasma biomarkers in a choline-deficient L-amino acid-defined diet rat NASH model. We analyzed liver samples by RNA-Seq and proteomics, revealing disease relevant signatures and a high correlation between mRNA and protein changes. Comparison to human data showed an overlap of inflammatory, metabolic, and developmental pathways. Using proteomics analysis of plasma we identified mainly secreted proteins that correlate with liver RNA and protein levels. We developed a multi-dimensional attribute ranking approach integrating multi-omics data with liver histology and prior knowledge uncovering known human markers, but also novel candidates. Using regression analysis, we show that the top-ranked markers were highly predictive for fibrosis in our model and hence can serve as preclinical plasma biomarkers. Our approach presented here illustrates the power of multi-omics analyses combined with plasma proteomics and is readily applicable to human biomarker discovery.<\/jats:p>","DOI":"10.1038\/s41598-020-58030-6","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T11:03:18Z","timestamp":1580209398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Biomarker discovery for chronic liver diseases by multi-omics \u2013 a preclinical case study"],"prefix":"10.1038","volume":"10","author":[{"given":"Daniel","family":"Veyel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Broermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Bretschneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Luippold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartlomiej","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-3544","authenticated-orcid":false,"given":"Wolfgang","family":"Rist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"58030_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md.) 64, 73\u201384, https:\/\/doi.org\/10.1002\/hep.28431 (2016).","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"Suppl 1","key":"58030_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/liv.13301","volume":"37","author":"P Bedossa","year":"2017","unstructured":"Bedossa, P. Pathology of non-alcoholic fatty liver disease. Liver Int 37(Suppl 1), 85\u201389, https:\/\/doi.org\/10.1111\/liv.13301 (2017).","journal-title":"Liver Int"},{"key":"58030_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong, R. J. et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148, 547\u2013555, https:\/\/doi.org\/10.1053\/j.gastro.2014.11.039 (2015).","journal-title":"Gastroenterology"},{"key":"58030_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","volume":"53","author":"Y Sumida","year":"2018","unstructured":"Sumida, Y. & Yoneda, M. Current and future pharmacological therapies for NAFLD\/NASH. J Gastroenterol 53, 362\u2013376, https:\/\/doi.org\/10.1007\/s00535-017-1415-1 (2018).","journal-title":"J Gastroenterol"},{"key":"58030_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VW Wong","year":"2018","unstructured":"Wong, V. W., Adams, L. A., de Ledinghen, V., Wong, G. L. & Sookoian, S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol 15, 461\u2013478, https:\/\/doi.org\/10.1038\/s41575-018-0014-9 (2018).","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"58030_CR6","doi-asserted-by":"publisher","first-page":"i4428","DOI":"10.1136\/bmj.i4428","volume":"354","author":"J Glen","year":"2016","unstructured":"Glen, J., Floros, L., Day, C. & Pryke, R. & Guideline Development, G. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ 354, i4428, https:\/\/doi.org\/10.1136\/bmj.i4428 (2016).","journal-title":"BMJ"},{"key":"58030_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/hep.28840","volume":"65","author":"K Liu","year":"2017","unstructured":"Liu, K., Xu, W. & Wong, V. W. Serum biomarkers for nonalcoholic fatty liver disease: Are we there yet? Hepatology (Baltimore, Md.) 65, 8\u201311, https:\/\/doi.org\/10.1002\/hep.28840 (2017).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"58030_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2011.01.031","volume":"55","author":"T Soga","year":"2011","unstructured":"Soga, T. et al. Serum metabolomics reveals gamma-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol 55, 896\u2013905, https:\/\/doi.org\/10.1016\/j.jhep.2011.01.031 (2011).","journal-title":"J Hepatol"},{"key":"58030_CR9","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1007\/s00125-013-2981-2","volume":"56","author":"M Oresic","year":"2013","unstructured":"Oresic, M. et al. Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia 56, 2266\u20132274, https:\/\/doi.org\/10.1007\/s00125-013-2981-2 (2013).","journal-title":"Diabetologia"},{"key":"58030_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1194\/jlr.P056002","volume":"56","author":"DL Gorden","year":"2015","unstructured":"Gorden, D. L. et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res 56, 722\u2013736, https:\/\/doi.org\/10.1194\/jlr.P056002 (2015).","journal-title":"J Lipid Res"},{"key":"58030_CR11","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.cgh.2016.05.046","volume":"14","author":"Y Zhou","year":"2016","unstructured":"Zhou, Y. et al. Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites. Clin Gastroenterol Hepatol 14, 1463\u20131472 e1466, https:\/\/doi.org\/10.1016\/j.cgh.2016.05.046 (2016).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"58030_CR12","doi-asserted-by":"publisher","first-page":"e8793","DOI":"10.15252\/msb.20188793","volume":"15","author":"L Niu","year":"2019","unstructured":"Niu, L. et al. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst Biol 15, e8793, https:\/\/doi.org\/10.15252\/msb.20188793 (2019).","journal-title":"Mol Syst Biol"},{"key":"58030_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/hep.23271","volume":"51","author":"LN Bell","year":"2010","unstructured":"Bell, L. N. et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.) 51, 111\u2013120, https:\/\/doi.org\/10.1002\/hep.23271 (2010).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"58030_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep43238","volume":"7","author":"GC Wood","year":"2017","unstructured":"Wood, G. C. et al. A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci Rep 7, 43238, https:\/\/doi.org\/10.1038\/srep43238 (2017).","journal-title":"Sci Rep"},{"key":"58030_CR15","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","volume":"22","author":"HH Hansen","year":"2017","unstructured":"Hansen, H. H. et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today 22, 1707\u20131718, https:\/\/doi.org\/10.1016\/j.drudis.2017.06.007 (2017).","journal-title":"Drug Discov Today"},{"key":"58030_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","volume":"65","author":"A Asgharpour","year":"2016","unstructured":"Asgharpour, A. et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol 65, 579\u2013588, https:\/\/doi.org\/10.1016\/j.jhep.2016.05.005 (2016).","journal-title":"J Hepatol"},{"key":"58030_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","volume":"69","author":"T Tsuchida","year":"2018","unstructured":"Tsuchida, T. et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 69, 385\u2013395, https:\/\/doi.org\/10.1016\/j.jhep.2018.03.011 (2018).","journal-title":"J Hepatol"},{"key":"58030_CR18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1194\/jlr.M800042-JLR200","volume":"49","author":"ME Rinella","year":"2008","unstructured":"Rinella, M. E. et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 49, 1068\u20131076, https:\/\/doi.org\/10.1194\/jlr.M800042-JLR200 (2008).","journal-title":"J Lipid Res"},{"issue":"5","key":"58030_CR19","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s10620-018-5395-7","volume":"64","author":"Kirstine S. T\u00f8lb\u00f8l","year":"2018","unstructured":"Tolbol, K. S. et al. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. Dig Dis Sci, https:\/\/doi.org\/10.1007\/s10620-018-5395-7 (2018).","journal-title":"Digestive Diseases and Sciences"},{"key":"58030_CR20","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1124\/dmd.109.027466","volume":"37","author":"CD Fisher","year":"2009","unstructured":"Fisher, C. D. et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 37, 2087\u20132094, https:\/\/doi.org\/10.1124\/dmd.109.027466 (2009).","journal-title":"Drug Metab Dispos"},{"key":"58030_CR21","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1124\/dmd.111.040592","volume":"39","author":"AD Lake","year":"2011","unstructured":"Lake, A. D. et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 39, 1954\u20131960, https:\/\/doi.org\/10.1124\/dmd.111.040592 (2011).","journal-title":"Drug Metab Dispos"},{"key":"58030_CR22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.cmet.2013.07.004","volume":"18","author":"M Ahrens","year":"2013","unstructured":"Ahrens, M. et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 18, 296\u2013302, https:\/\/doi.org\/10.1016\/j.cmet.2013.07.004 (2013).","journal-title":"Cell Metab"},{"key":"58030_CR23","doi-asserted-by":"publisher","first-page":"e46584","DOI":"10.1371\/journal.pone.0046584","volume":"7","author":"J Starmann","year":"2012","unstructured":"Starmann, J. et al. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One 7, e46584, https:\/\/doi.org\/10.1371\/journal.pone.0046584 (2012).","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"58030_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/liv.13643","volume":"38","author":"AR Araujo","year":"2018","unstructured":"Araujo, A. R., Rosso, N., Bedogni, G., Tiribelli, C. & Bellentani, S. Global epidemiology of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: What we need in the future. Liver Int 38(Suppl 1), 47\u201351, https:\/\/doi.org\/10.1111\/liv.13643 (2018).","journal-title":"Liver Int"},{"key":"58030_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.molmet.2018.12.004","volume":"20","author":"X Xiong","year":"2019","unstructured":"Xiong, X. et al. Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi. Mol Metab 20, 128\u2013137, https:\/\/doi.org\/10.1016\/j.molmet.2018.12.004 (2019).","journal-title":"Mol Metab"},{"key":"58030_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4254\/wjh.v8.i16.673","volume":"8","author":"MN Kristiansen","year":"2016","unstructured":"Kristiansen, M. N. et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J Hepatol 8, 673\u2013684, https:\/\/doi.org\/10.4254\/wjh.v8.i16.673 (2016).","journal-title":"World J Hepatol"},{"key":"58030_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/hep.21763","volume":"46","author":"P Puri","year":"2007","unstructured":"Puri, P. et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.) 46, 1081\u20131090, https:\/\/doi.org\/10.1002\/hep.21763 (2007).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"58030_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/hep.25789","volume":"57","author":"C Savard","year":"2013","unstructured":"Savard, C. et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology (Baltimore, Md.) 57, 81\u201392, https:\/\/doi.org\/10.1002\/hep.25789 (2013).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"58030_CR29","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1093\/emboj\/17.6.1606","volume":"17","author":"T Sasaki","year":"1998","unstructured":"Sasaki, T., Brakebusch, C., Engel, J. & Timpl, R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J 17, 1606\u20131613, https:\/\/doi.org\/10.1093\/emboj\/17.6.1606 (1998).","journal-title":"EMBO J"},{"key":"58030_CR30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00535-014-1007-2","volume":"50","author":"M Abe","year":"2015","unstructured":"Abe, M. et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 50, 776\u2013784, https:\/\/doi.org\/10.1007\/s00535-014-1007-2 (2015).","journal-title":"J Gastroenterol"},{"key":"58030_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clinbiochem.2018.04.017","volume":"56","author":"H Cai","year":"2018","unstructured":"Cai, H. et al. Serum retinol binding protein 4 and galectin-3 binding protein as novel markers for postmenopausal nonalcoholic fatty liver disease. Clin Biochem 56, 95\u2013101, https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.04.017 (2018).","journal-title":"Clin Biochem"},{"key":"58030_CR32","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/prca.201200137","volume":"7","author":"Y Kamada","year":"2013","unstructured":"Kamada, Y. et al. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics Clin Appl 7, 648\u2013656, https:\/\/doi.org\/10.1002\/prca.201200137 (2013).","journal-title":"Proteomics Clin Appl"},{"key":"58030_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/apt.13431","volume":"43","author":"K Ura","year":"2016","unstructured":"Ura, K. et al. Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther 43, 114\u2013124, https:\/\/doi.org\/10.1111\/apt.13431 (2016).","journal-title":"Aliment Pharmacol Ther"},{"key":"58030_CR34","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.kjms.2017.05.017","volume":"33","author":"CI Huang","year":"2017","unstructured":"Huang, C. I. et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients. Kaohsiung J Med Sci 33, 394\u2013399, https:\/\/doi.org\/10.1016\/j.kjms.2017.05.017 (2017).","journal-title":"Kaohsiung J Med Sci"},{"key":"58030_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41424-018-0020-9","volume":"9","author":"LY Mak","year":"2018","unstructured":"Mak, L. Y. et al. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol 9, 163, https:\/\/doi.org\/10.1038\/s41424-018-0020-9 (2018).","journal-title":"Clin Transl Gastroenterol"},{"key":"58030_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.0105-2896.2005.00278.x","volume":"206","author":"CS Kaetzel","year":"2005","unstructured":"Kaetzel, C. S. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev 206, 83\u201399, https:\/\/doi.org\/10.1111\/j.0105-2896.2005.00278.x (2005).","journal-title":"Immunol Rev"},{"key":"58030_CR37","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1093\/jnci\/djr360","volume":"103","author":"J Ai","year":"2011","unstructured":"Ai, J. et al. The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J Natl Cancer Inst 103, 1696\u20131712, https:\/\/doi.org\/10.1093\/jnci\/djr360 (2011).","journal-title":"J Natl Cancer Inst"},{"key":"58030_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1136\/jcp.45.7.568","volume":"45","author":"D Kvale","year":"1992","unstructured":"Kvale, D. et al. Circulating secretory component in relation to early diagnosis and treatment of liver metastasis from colorectal carcinomas. J Clin Pathol 45, 568\u2013571 (1992).","journal-title":"J Clin Pathol"},{"key":"58030_CR39","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1074\/jbc.274.11.6875","volume":"274","author":"DT Humphreys","year":"1999","unstructured":"Humphreys, D. T., Carver, J. A., Easterbrook-Smith, S. B. & Wilson, M. R. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274, 6875\u20136881 (1999).","journal-title":"J Biol Chem"},{"key":"58030_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0065-230X(09)04006-8","volume":"104","author":"A Wyatt","year":"2009","unstructured":"Wyatt, A., Yerbury, J., Poon, S., Dabbs, R. & Wilson, M. Chapter 6: The chaperone action of Clusterin and its putative role in quality control of extracellular protein folding. Adv Cancer Res 104, 89\u2013114, https:\/\/doi.org\/10.1016\/S0065-230X(09)04006-8 (2009).","journal-title":"Adv Cancer Res"},{"key":"58030_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1471-230X-10-115","volume":"10","author":"Y Lu","year":"2010","unstructured":"Lu, Y. et al. Peroxiredoxin 2: a potential biomarker for early diagnosis of hepatitis B virus related liver fibrosis identified by proteomic analysis of the plasma. BMC Gastroenterol 10, 115, https:\/\/doi.org\/10.1186\/1471-230X-10-115 (2010).","journal-title":"BMC Gastroenterol"},{"key":"58030_CR42","doi-asserted-by":"publisher","first-page":"e39603","DOI":"10.1371\/journal.pone.0039603","volume":"7","author":"B Gangadharan","year":"2012","unstructured":"Gangadharan, B. et al. Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. PLoS One 7, e39603, https:\/\/doi.org\/10.1371\/journal.pone.0039603 (2012).","journal-title":"PLoS One"},{"key":"58030_CR43","doi-asserted-by":"publisher","first-page":"466","DOI":"10.2337\/dc18-0870","volume":"42","author":"D Bradley","year":"2019","unstructured":"Bradley, D. et al. Clusterin Impairs Hepatic Insulin Sensitivity and Adipocyte Clusterin Associates With Cardiometabolic Risk. Diabetes Care 42, 466\u2013475, https:\/\/doi.org\/10.2337\/dc18-0870 (2019).","journal-title":"Diabetes Care"},{"key":"58030_CR44","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.4049\/jimmunol.171.10.5537","volume":"171","author":"D Pilling","year":"2003","unstructured":"Pilling, D., Buckley, C. D., Salmon, M. & Gomer, R. H. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 171, 5537\u20135546, https:\/\/doi.org\/10.4049\/jimmunol.171.10.5537 (2003).","journal-title":"J Immunol"},{"key":"58030_CR45","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.3389\/fimmu.2018.02328","volume":"9","author":"D Pilling","year":"2018","unstructured":"Pilling, D. & Gomer, R. H. The Development of Serum Amyloid P as a Possible Therapeutic. Front Immunol 9, 2328, https:\/\/doi.org\/10.3389\/fimmu.2018.02328 (2018).","journal-title":"Front Immunol"},{"key":"58030_CR46","doi-asserted-by":"publisher","first-page":"G746","DOI":"10.1152\/ajpgi.00485.2009","volume":"298","author":"LN Bell","year":"2010","unstructured":"Bell, L. N. et al. Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol 298, G746\u2013754, https:\/\/doi.org\/10.1152\/ajpgi.00485.2009 (2010).","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"58030_CR47","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1210\/endo.137.8.8754751","volume":"137","author":"AD Dunn","year":"1996","unstructured":"Dunn, A. D., Myers, H. E. & Dunn, J. T. The combined action of two thyroidal proteases releases T4 from the dominant hormone-forming site of thyroglobulin. Endocrinology 137, 3279\u20133285, https:\/\/doi.org\/10.1210\/endo.137.8.8754751 (1996).","journal-title":"Endocrinology"},{"key":"58030_CR48","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1046\/j.1365-2443.2002.00593.x","volume":"7","author":"MA Della Fazia","year":"2002","unstructured":"Della Fazia, M. A. et al. lal-1: a differentially expressed novel gene during proliferation in liver regeneration and in hepatoma cells. Genes Cells 7, 1183\u20131190, https:\/\/doi.org\/10.1046\/j.1365-2443.2002.00593.x (2002).","journal-title":"Genes Cells"},{"key":"58030_CR49","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/j.biocel.2005.03.009","volume":"37","author":"J Huxley-Jones","year":"2005","unstructured":"Huxley-Jones, J., Apte, S. S., Robertson, D. L. & Boot-Handford, R. P. The characterisation of six ADAMTS proteases in the basal chordate Ciona intestinalis provides new insights into the vertebrate ADAMTS family. Int J Biochem Cell Biol 37, 1838\u20131845, https:\/\/doi.org\/10.1016\/j.biocel.2005.03.009 (2005).","journal-title":"Int J Biochem Cell Biol"},{"key":"58030_CR50","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/ng.199","volume":"40","author":"C Le Goff","year":"2008","unstructured":"Le Goff, C. et al. ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. Nat Genet 40, 1119\u20131123, https:\/\/doi.org\/10.1038\/ng.199 (2008).","journal-title":"Nat Genet"},{"key":"58030_CR51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.matbio.2018.05.003","volume":"75-76","author":"R Aviram","year":"2019","unstructured":"Aviram, R. et al. Interactions between lysyl oxidases and ADAMTS proteins suggest a novel crosstalk between two extracellular matrix families. Matrix Biol 75-76, 114\u2013125, https:\/\/doi.org\/10.1016\/j.matbio.2018.05.003 (2019).","journal-title":"Matrix Biol"},{"key":"58030_CR52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1242\/dmm.017046","volume":"8","author":"D Hubmacher","year":"2015","unstructured":"Hubmacher, D., Wang, L. W., Mecham, R. P., Reinhardt, D. P. & Apte, S. S. Adamtsl2 deletion results in bronchial fibrillin microfibril accumulation and bronchial epithelial dysplasia\u2013a novel mouse model providing insights into geleophysic dysplasia. Dis Model Mech 8, 487\u2013499, https:\/\/doi.org\/10.1242\/dmm.017046 (2015).","journal-title":"Dis Model Mech"},{"key":"58030_CR53","doi-asserted-by":"publisher","first-page":"942","DOI":"10.15252\/msb.20156297","volume":"13","author":"PE Geyer","year":"2017","unstructured":"Geyer, P. E., Holdt, L. M., Teupser, D. & Mann, M. Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol 13, 942, https:\/\/doi.org\/10.15252\/msb.20156297 (2017).","journal-title":"Mol Syst Biol"},{"key":"58030_CR54","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1038\/mtna.2014.49","volume":"3","author":"JC Rohloff","year":"2014","unstructured":"Rohloff, J. C. et al. Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents. Mol Ther Nucleic Acids 3, e201, https:\/\/doi.org\/10.1038\/mtna.2014.49 (2014).","journal-title":"Mol Ther Nucleic Acids"},{"key":"58030_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.185","volume":"4","author":"JF Sollner","year":"2017","unstructured":"Sollner, J. F. et al. An RNA-Seq atlas of gene expression in mouse and rat normal tissues. Scientific data 4, 170185, https:\/\/doi.org\/10.1038\/sdata.2017.185 (2017).","journal-title":"Scientific data"},{"key":"58030_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics (Oxford, England) 29, 15\u201321, https:\/\/doi.org\/10.1093\/bioinformatics\/bts635 (2013).","journal-title":"Bioinformatics (Oxford, England)"},{"key":"58030_CR57","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930, https:\/\/doi.org\/10.1093\/bioinformatics\/btt656 (2014).","journal-title":"Bioinformatics"},{"key":"58030_CR58","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47, https:\/\/doi.org\/10.1093\/nar\/gkv007 (2015).","journal-title":"Nucleic Acids Res."},{"key":"58030_CR59","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological) 57, 289\u2013300 (1995).","journal-title":"Series B (Methodological)"},{"key":"58030_CR60","unstructured":"R Core Team R: A language and environment for statistical computing. R Foundation for Statistical Computing, V., Austria. URL https:\/\/www.R-project.org\/ (2018)."},{"key":"58030_CR61","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/bioinformatics\/btm069","volume":"23","author":"W Stacklies","year":"2007","unstructured":"Stacklies, W., Redestig, H., Scholz, M., Walther, D. & Selbig, J. pcaMethods\u2013a bioconductor package providing PCA methods for incomplete data. Bioinformatics (Oxford, England) 23, 1164\u20131167, https:\/\/doi.org\/10.1093\/bioinformatics\/btm069 (2007).","journal-title":"Bioinformatics (Oxford, England)"},{"key":"58030_CR62","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 13, 731\u2013740, https:\/\/doi.org\/10.1038\/nmeth.3901 (2016).","journal-title":"Nat Methods"},{"key":"58030_CR63","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1074\/mcp.M113.035600","volume":"13","author":"L Fagerberg","year":"2014","unstructured":"Fagerberg, L. et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Molecular & cellular proteomics: MCP 13, 397\u2013406, https:\/\/doi.org\/10.1074\/mcp.M113.035600 (2014).","journal-title":"Molecular & cellular proteomics: MCP"},{"key":"58030_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/srep44867","volume":"7","author":"JY Chen","year":"2017","unstructured":"Chen, J. Y. et al. Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells. Sci Rep 7, 44867, https:\/\/doi.org\/10.1038\/srep44867 (2017).","journal-title":"Sci Rep"},{"key":"58030_CR65","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/1044-0305(94)80016-2","volume":"5","author":"JK Eng","year":"1994","unstructured":"Eng, J. K., McCormack, A. L. & Yates, J. R. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 5, 976\u2013989, https:\/\/doi.org\/10.1016\/1044-0305(94)80016-2 (1994).","journal-title":"J Am Soc Mass Spectrom"},{"key":"58030_CR66","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nmeth1113","volume":"4","author":"L Kall","year":"2007","unstructured":"Kall, L., Canterbury, J. D., Weston, J., Noble, W. S. & MacCoss, M. J. Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat Methods 4, 923\u2013925, https:\/\/doi.org\/10.1038\/nmeth1113 (2007).","journal-title":"Nat Methods"},{"key":"58030_CR67","doi-asserted-by":"publisher","first-page":"D442","DOI":"10.1093\/nar\/gky1106","volume":"47","author":"Y Perez-Riverol","year":"2019","unstructured":"Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res 47, D442\u2013D450, https:\/\/doi.org\/10.1093\/nar\/gky1106 (2019).","journal-title":"Nucleic Acids Res"},{"key":"58030_CR68","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nprot.2013.092","volume":"8","author":"H Mi","year":"2013","unstructured":"Mi, H., Muruganujan, A., Casagrande, J. T. & Thomas, P. D. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 8, 1551\u20131566, https:\/\/doi.org\/10.1038\/nprot.2013.092 (2013).","journal-title":"Nat Protoc"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58030-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58030-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58030-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T06:11:29Z","timestamp":1670307089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58030-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["58030"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-58030-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"2 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.W. was financially supported by Boehringer Ingelheim Pharma GmbH & Co. KG (BI). At the time of writing this article D.V., E.S., W.R., B.K., T.B., A.B. are full time employees of BI. All authors declare no additional competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1314"}}